RxDoctor Payments Data

Edward Neff, MD

Cardiovascular Disease · Coral Gables, FLNPI 1891775300

Payments from drug & device makers

$5,008in general payments, 2019–2025

Across 250 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$457
  • E.r. Squibb & Sons, L.L.C.$438
  • Pfizer$413
  • Novo Nordisk$397
  • Johnson & Johnson$394
  • Kowa Pharmaceuticals America, Inc.$384
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$4,95899%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,008 in reported general payments places this provider in the 55th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$202,558
Medicare patients
411
Services billed
4,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban198$182,355
Repatha SureclickEvolocumab114$113,929
OzempicSemaglutide61$62,459
XareltoRivaroxaban36$47,969
VascepaIcosapent Ethyl57$36,828
JardianceEmpagliflozin11$16,062
Praluent PenAlirocumab20$15,776
EntrestoSacubitril/Valsartan23$15,374
MultaqDronedarone Hcl13$15,227
WegovySemaglutide11$14,084
JanuviaSitagliptin Phosphate12$12,213
NexlizetBempedoic Acid/Ezetimibe18$11,051
LivaloPitavastatin Calcium15$9,291
MyrbetriqMirabegron17$8,947
LinzessLinaclotide14$8,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$413$185,213232 claims
Novo NordiskOzempic, Wegovy$397$76,54372 claims
Johnson & JohnsonXarelto$394$47,96936 claims
Boehringer IngelheimJardiance$294$16,06211 claims
NovartisEntresto$329$15,37423 claims
Sanofi-aventis U.S. LLCMultaq$185$15,22713 claims
MerckJanuvia$384$12,21312 claims
Esperion Therapeutics, Inc.Nexlizet$226$11,05118 claims
Kowa Pharmaceuticals America, Inc.Livalo$384$9,29115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →